CA
ANAB icon

Continuum Advisory’s AnaptysBio ANAB Stock Holding History

Continuum Advisory’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-19
Closed -$383 – 1858
2024
Q3 		$383 Buy
+19
New +$649 ﹤0.01% 1834

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Continuum Advisory's ANAB Position: Q4 2024 in Review

Continuum Advisory sold out of AnaptysBio (ANAB) in Q4 2024, closing a stake of 19 shares — an estimated $383 sold.

Continuum Advisory first reported a position in ANAB in Q3 2024 and held it in 1 quarter. The position peaked at $383 in Q3 2024. 135 funds tracked by Wall St. Rank hold ANAB as of Q4 2024.

  • Continuum Advisory reported no remaining AnaptysBio position as of Q4 2024 after selling out during the quarter.
  • Continuum Advisory sold 19 AnaptysBio shares in Q4 2024, an estimated $383.
  • Continuum Advisory first reported a position in AnaptysBio in Q3 2024 and held it in 1 quarter.
  • Continuum Advisory's AnaptysBio position peaked at $383 in Q3 2024.
  • 135 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2024.

Based on Continuum Advisory's 13F filing for Q4 2024, filed 18 Feb 2025.